Semaphorin 3C (Sema3C) Inhibitor Therapeutics, Methods, and Uses

Abstract

Provided are methods, uses and pharmaceutical compositions for treatment of prostate cancer with a SEMA3C inhibitor in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the SEMA3C inhibitor may be selected from one or more of the following: an antibody, a SEMA3C peptide, an antisense RNA, a siRNA, a shRNA or a small molecule.

1 - 64 . (canceled) 
     
     
         65 . A pharmaceutical composition comprising a therapeutically effective amount of an anti-SEMA3C antibody having SEMA3C inhibitory activity in combination with a physiologically acceptable carrier. 
     
     
         66 . The pharmaceutical composition of  claim 65 , wherein the anti-SEMA3C antibody is selected from one or more of the following: a polyclonal antibody; a monoclonal antibody; an antigen binding fragment of an antibody; or a single chain antibody. 
     
     
         67 . The pharmaceutical composition of  claim 65 , wherein the anti-SEMA3C antibody is a monoclonal antibody. 
     
     
         68 . The pharmaceutical composition of  claim 65 , wherein the anti-SEMA3C antibody is a polyclonal antibody. 
     
     
         69 . The pharmaceutical composition of  claim 65 , wherein the anti-SEMA3C antibody is an antigen binding fragment of an antibody. 
     
     
         70 . The pharmaceutical composition of  claim 65 , wherein the anti-SEMA3C antibody is a single chain antibody. 
     
     
         71 . The pharmaceutical composition of  claim 65 , formulated for administration with an androgen deprivation therapy. 
     
     
         72 . The pharmaceutical composition of  claim 71 , wherein androgen deprivation therapy is selected from one or more of the following: a luteinizing hormone-releasing hormone (LHRH) analog; an anti-androgen compound; and an adrenal androgen inhibitor. 
     
     
         73 . The pharmaceutical composition of  claim 72 , wherein the androgen deprivation therapy is a luteinizing hormone-releasing hormone (LHRH) analog. 
     
     
         74 . The pharmaceutical composition of  claim 72 , wherein the androgen deprivation therapy is an anti-androgen treatment. 
     
     
         75 . The pharmaceutical composition of  claim 72 , wherein the androgen deprivation therapy is an adrenal androgen inhibitor. 
     
     
         76 . The pharmaceutical composition of  claim 65 , formulated for administration with a further chemotherapeutic regimen. 
     
     
         77 . The pharmaceutical composition of  claim 71 , further comprising a further chemotherapeutic regimen. 
     
     
         78 . The pharmaceutical composition of  claim 65 , wherein the anti-SEMA3C antibody having SEMA3C inhibitory activity is targeted to androgen receptor (AR) positive prostate cancer. 
     
     
         79 . The pharmaceutical composition of  claim 78 , wherein the anti-SEMA3C antibody is targeted to prostate cancer before the prostate cancer becomes androgen independent. 
     
     
         80 . The pharmaceutical composition of  claim 65 , wherein the anti-SEMA3C antibody having SEMA3C inhibitory activity is targeted to androgen-dependent prostate cancer.